Perspectives
25 Medicare contracts earn quality bonuses
CMS releases its latest Star Ratings: A look at Prime-supported Medicare contracts that earned quality bonus payments from getting a 4+ Star Rating
November 11, 2022“These results highlight how Prime works to make health care more affordable for members,” says Kip Haffner, vice president, government programs. “The payments are worth hundreds of millions of dollars to our health plan clients to help them better serve their members.”
These results mean that 73% of our Medicare Advantage Prescription Drug (MAPD) members are covered by a plan with an overall rating of 4 or more Stars.
Stars and total drug management
Star ratings have 40 measures that combine for one rating:
- Part C measures mostly the health plan and medical benefit
- Part D measures the drug benefit
As a pharmacy benefit manager, Prime influences many of the Part D measures reflecting:
- Operations
- Customer experience
- Medication adherence
Continuous improvement
CMS evaluates performance data each year and may adjust the measures for all metrics. This makes it more challenging to earn higher Star ratings.
“We have a strong foundation,” explains Kip Haffner. “Our adherence programs are clinically sound and validated by research. Our operations are becoming industry-leading. We build on these strengths every year. CMS can raise the bar, and here at Prime, we’ll keep innovating,” he said.
Prime continues to innovate with our Blue Plan clients providing products and services that deliver improved quality to members.
Take a look at some of the award-winning research behind these products. SmartAdherence™ Missed Refill Program, lower cost share generics and Quality-Based Network. And you’ll see how Prime is helping to make health care work better.
Related news
Perspectives
July 25, 2024
Quarterly Drug Pipeline: July 2024
Clinical insights and competitive intelligence on anticipated drugs in development
Perspectives
July 22, 2024
Oncology Insights: 2024 ASCO Annual Meeting key findings
Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions
Perspectives
July 16, 2024
LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast
In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts